Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: A subanalysis of the Treating to New Targets (TNT) study

Diabetes, Obesity and Metabolism

Volumn 18, Issue 1, 2016, Pages 56-63

  Deedwania, P C ^a   Shepherd, J ^b   Breazna, A ^c   Demicco, D A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

Atorvastatin; Cardiovascular events; Metabolic syndrome

Indexed keywords

ATORVASTATIN; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PREDICTION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DIET RESTRICTION; DRUG EFFECTS; MIDDLE AGED; PREDICTIVE VALUE; RISK FACTOR;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FASTING; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TRIGLYCERIDES;

EID: 84954405833     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12581     Document Type: Article

References (28)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
2. Grundy SM, Cleeman JI, Daniels SR etal. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
3. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
4. Girman CJ, Rhodes T, Mercuri M etal. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136-141.
5. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42-46.
6. Deedwania P, Barter P, Carmena R etal. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368: 919-928.
7. Ärnlöv J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010; 121: 230-236.
8. Mente A, Yusuf S, Islam S etal. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26, 903 subjects from 52 countries. J Am Coll Cardiol 2010; 55: 2390-2398.
9. Gami AS, Witt BJ, Howard DE etal. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403-414.
10. Mottillo S, Filion KB, Genest J etal. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-1132.
11. Solymoss BC, Bourassa MG, Campeau L etal. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004; 93: 159-164.
12. Sattar N, Gaw A, Scherbakova O etal. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419.
13. Schillaci G, Pirro M, Vaudo G etal. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43: 1817-1822.
14. Eberly LE, Prineas R, Cohen JD etal. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006; 29: 123-130.
15. Franco OH, Massaro JM, Civil J, Cobain MR, O'Malley B, D'Agostino RB Sr. Trajectories of entering the metabolic syndrome: the Framingham Heart Study. Circulation 2009; 120: 1943-1950.
16. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
17. Sattar N, McConnachie A, Shaper AG etal. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371: 1927-1935.
18. Salminen M, Kuoppamaki M, Vahlberg T, Raiha I, Irjala K, Kivela SL. Metabolic syndrome and vascular risk: a 9-year follow-up among the aged in Finland. Acta Diabetol 2011; 48: 157-165.
19. LaRosa JC, Grundy SM, Waters DD etal. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
20. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93: 154-158.
21. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33 (Suppl. 1): S11-S61.
22. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009; 13: 1-7.
23. Alberti KG, Eckel RH, Grundy SM etal. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; international Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
24. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2010; 2: 180-193.
25. Grundy SM, Cleeman JI, Merz CN etal. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
26. Smith SC Jr, Benjamin EJ, Bonow RO etal. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Hart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-2473.
27. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444-2449.
28. Ryan MC, Fenster Farin HM, Abbasi F, Reaven GM. Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease. Am J Cardiol 2008; 102: 40-46.